【联合开发心脏药物III期试验未达主要终点 阿斯利康(AZN.US)与Ionis(IONS.US)股价暴跌】智通财经APP获悉,阿斯利康(AZN.US)与Ionis(IONS.US)联合开发的一款实验性心脏病药物在后期临床试验中未能达到主要疗效终点,该股伦敦挂牌股价周三暴跌近10%,截至发稿,周三美股盘前跌8.67%,Ionis股价盘前亦下跌逾8%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.